The history of brain drug delivery is reviewed beginning with the first demonstration, in 1914,
that a drug for syphilis, salvarsan, did not enter the brain, due to the presence of a blood …

Introduction: There are 2 misconceptions about the cerebrospinal fluid (CSF), the blood-
brain barrier (BBB), and brain drug delivery, which date back to the discovery of a barrier …

Alzheimer's disease (AD) and treatment of the brain in aging require the development of
new biologic drugs, such as recombinant proteins or gene therapies. Biologics are large …

The blood–brain barrier (BBB) prevents the brain uptake of most pharmaceuticals. This
property arises from the epithelial-like tight junctions within the brain capillary endothelium …

Despite the enormity of the societal and health burdens caused by Alzheimer's disease
(AD), there have been no FDA approvals for new therapeutics for AD since 2003. This …

The blood-brain barrier (BBB) is formed by the brain capillary endothelium and excludes
from the brain∼ 100% of large-molecule neurotherapeutics and more than 98% of all small …

Brain-derived neurotrophic factor (BDNF) is expressed at high levels in hippocampal
neurons, and its expression is modulated by neural activity. Knockout mice can be used to …

Brain-derived neurotrophic factor (BDNF) is a small dimeric protein, structurally related to
nerve growth factor, which is abundantly and widely expressed in the adult mammalian …

The development of new drugs for the brain has not kept pace with progress in the
molecular neurosciences, because the majority of new drugs discovered do not cross the …

The presence of a blood-brain barrier (BBB) and a blood-cerebrospinal fluid barrier presents
a huge challenge for effective delivery of therapeutics to the central nervous system (CNS) …